- Oops!Something went wrong.Please try again later.
The analyst believes there is a high unmet need in the oral space for psoriasis, given that approved therapies such as Amgen Inc's (NASDAQ: AMGN) Otezla only have PASI-75 rates of ~30%. Biologics have PASI-75 rates of up to 90%, but Otezla sales are over $2 billion annually despite this factor.
DICE's lead product, DC-806 is currently in a Phase 1 study (healthy volunteers and psoriasis patients) with full data expected in 3Q22 (H.C. Wainwright estimates mid/late August).
If efficacy and safety data are positive, it will validate the company's DELSCAPE technology platform, and DICE would be the furthest along in developing an oral IL-17 inhibitor.
In preclinical models, DC-806 could match the level of IL-17 inhibition and the anti-inflammatory effect of Cosentyx (anti-IL-17 antibody), giving added confidence that DC-806 could have higher efficacy rates than some approved biologics.
However, as an oral treatment, lower efficacy than anti-IL-17 antibodies would still be sufficient, H.C. Wainwright writes.
Price Action: DICE shares are down 0.44% at $16.01 during the market session on the last check Monday.
Latest Ratings for DICE
B of A Securities
Initiates Coverage On
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.